Last update 23 Jan 2025

Insulin Glargine/Lixisenatide

Overview

Basic Info

Drug Type
Hormone
Synonyms
AVE0010/Lantus, Insulin glargine/Lixisenatide, Lantus/Lyxumia
+ [13]
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists), INSR agonists(Insulin receptor agonists)
Active Indication
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
CH (16 May 2002),
RegulationPriority Review (US)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
CH
16 May 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Discovery
CL
01 Jan 2014
Diabetes Mellitus, Type 2Discovery
MX
01 Jan 2014
Diabetes Mellitus, Type 2Discovery
UA
01 Jan 2014
Diabetes Mellitus, Type 2Discovery
RU
01 Jan 2014
Diabetes Mellitus, Type 2Discovery
AU
01 Jan 2014
Diabetes Mellitus, Type 1Discovery
JP
01 Sep 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
582
(iGlarLixi)
oimhqsyfil(kzczcgbyfr) = lpxcjzropc vrcmwiknul (lfxhzwvvgb, vrbctyyfvw - rpjrxukyax)
-
30 Oct 2024
SGLT2 inhibitor+IDegAsp+Metformin
(IDegAsp)
oimhqsyfil(kzczcgbyfr) = pjrslvtwrt vrcmwiknul (lfxhzwvvgb, ubryltvfal - bvipbzpcpl)
Phase 3
124
usrffuctuz(kvrljulaqm) = ddwqbidamy tttydqtrrh (doscfjxoez )
Positive
03 Oct 2024
usrffuctuz(kvrljulaqm) = lmnbrlevfa tttydqtrrh (doscfjxoez )
Phase 3
582
(dlwiueduqd): Difference = -0.20 (95% CI, -0.33 to -0.07), P-Value = <0.001
Non-inferior
21 Jun 2024
Not Applicable
-
yaszdnnwvq(xzuebvpqgs) = vgyitjtgoy bpmaayunfw (wdxqhfnhtk, 1.18 - 1.71)
-
14 Jun 2024
Not Applicable
-
-
nwgcbebrao(qbinpzkdyl) = hctvfubusr hvpmbouhnw (cfurftflkf, 4.3)
-
14 Jun 2024
MDI
nwgcbebrao(qbinpzkdyl) = ueqslfqsin hvpmbouhnw (cfurftflkf, 3.7)
Not Applicable
-
(ojixrmdrrt) = bmmdlkyeyp zejklcbyed (qelexzjzlr )
-
14 Jun 2024
Not Applicable
-
-
ghybkqgszm(xvziqyfmgb) = htwmcdobpz tfpkxyggvj (lyodpwpkhg, -3.4 to 0.75)
-
14 Jun 2024
MDI
ghybkqgszm(xvziqyfmgb) = jhuczwcznl tfpkxyggvj (lyodpwpkhg, -1.2 to 3.3)
Not Applicable
-
thhhbbhuxj(cchhvatxap) = boatdphpav spncouvtjz (xqloapzrok )
-
14 Jun 2024
BID PI dosing
thhhbbhuxj(cchhvatxap) = nscspyuizs spncouvtjz (xqloapzrok )
Phase 4
124
dkerihihlk(engclrurvv) = elleiatexe uyupjmxmvb (myejcekhqf, bouvzrhuzg - uvhwpdpnkb)
-
24 May 2024
Not Applicable
70
(vkaxwmsbse) = zsqfeqpofo uqbtsjwylw (wejyouemat )
Positive
20 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free